Integrated Analysis of Altered lncRNA, circRNA, microRNA, and mRNA Expression in Hepatocellular Carcinoma Carrying TERT Promoter Mutations

References

• Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6. doi:10.1038/s41572-020-00240-3
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Zucman-Rossi J, Villanueva A, Nault JC, Llovet JM. Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology. 2015;149(5):1226–1239.e1224. doi:10.1053/j.gastro.2015.05.061
   PubMed Web of Science ®Google Scholar
• Blackburn EH, Epel ES, Lin J. Human telomere biology: a contributory and interactive factor in aging, disease risks, and protection. Science. 2015;350(6265):1193–1198. doi:10.1126/science.aab3389
   PubMed Web of Science ®Google Scholar
• Wu RA, Upton HE, Vogan JM, Collins K. Telomerase mechanism of telomere synthesis. Annu Rev Biochem. 2017;86:439–460. doi:10.1146/annurev-biochem-061516-045019
   PubMed Web of Science ®Google Scholar
• Heidenreich B, Kumar R. TERT promoter mutations in telomere biology. Mutat Res Rev Mutat Res. 2017;771:15–31. doi:10.1016/j.mrrev.2016.11.002
   PubMed Web of Science ®Google Scholar
• Liu T, Yuan X, Xu D. Cancer-specific Telomerase Reverse Transcriptase (TERT) promoter mutations: biological and clinical implications. Genes. 2016;7:7. doi:10.3390/genes7070038
   PubMed Web of Science ®Google Scholar
• Liu X, Wu G, Shan Y, Hartmann C, von Deimling A, Xing M. Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma. Cell Cycle. 2013;12(10):1637–1638. doi:10.4161/cc.24662
   PubMed Web of Science ®Google Scholar
• Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA. Highly recurrent TERT promoter mutations in human melanoma. Science. 2013;339(6122):957–959. doi:10.1126/science.1229259
   PubMed Web of Science ®Google Scholar
• Nault JC, Zucman-Rossi J. TERT promoter mutations in primary liver tumors. Clin Res Hepatol Gastroenterol. 2016;40(1):9–14. doi:10.1016/j.clinre.2015.07.006
   PubMed Web of Science ®Google Scholar
• Nault JC, Calderaro J, Di Tommaso L, et al. Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. Hepatology. 2014;60(6):1983–1992. doi:10.1002/hep.27372
   PubMed Web of Science ®Google Scholar
• Fredriksson NJ, Ny L, Nilsson JA, Larsson E. Systematic analysis of noncoding somatic mutations and gene expression alterations across 14 tumor types. Nat Genet. 2014;46(12):1258–1263. doi:10.1038/ng.3141
   PubMed Web of Science ®Google Scholar
• Pópulo H, Boaventura P, Vinagre J, et al. TERT promoter mutations in skin cancer: the effects of sun exposure and X-irradiation. J Invest Dermatol. 2014;134(8):2251–2257. doi:10.1038/jid.2014.163
   PubMed Web of Science ®Google Scholar
• Allory Y, Beukers W, Sagrera A, et al. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Eur Urol. 2014;65(2):360–366. doi:10.1016/j.eururo.2013.08.052
   PubMed Web of Science ®Google Scholar
• Chen YL, Jeng YM, Chang CN, et al. TERT promoter mutation in resectable hepatocellular carcinomas: a strong association with hepatitis C infection and absence of hepatitis B infection. Int J Surg. 2014;12(7):659–665. doi:10.1016/j.ijsu.2014.05.066
   PubMed Web of Science ®Google Scholar
• Anastasiadou E, Jacob LS, Slack FJ. Non-coding RNA networks in cancer. Nat Rev Cancer. 2018;18(1):5–18. doi:10.1038/nrc.2017.99
   PubMed Web of Science ®Google Scholar
• Peng WX, Koirala P, Mo YY. LncRNA-mediated regulation of cell signaling in cancer. Oncogene. 2017;36(41):5661–5667. doi:10.1038/onc.2017.184
   PubMed Web of Science ®Google Scholar
• Shen H, Liu B, Xu J, et al. Circular RNAs: characteristics, biogenesis, mechanisms and functions in liver cancer. J Hematol Oncol. 2021;14(1):134. doi:10.1186/s13045-021-01145-8
   PubMed Web of Science ®Google Scholar
• Liu S, Qiu J, He G, et al. LncRNA MALAT1 acts as a miR-125a-3p sponge to regulate FOXM1 expression and promote hepatocellular carcinoma progression. J Cancer. 2019;10(26):6649–6659. doi:10.7150/jca.29213
   PubMed Web of Science ®Google Scholar
• Abbastabar M, Sarfi M, Golestani A, Khalili E. lncRNA involvement in hepatocellular carcinoma metastasis and prognosis. Excli J. 2018;17:900–913. doi:10.17179/excli2018-1541
   PubMed Web of Science ®Google Scholar
• Huang G, Liang M, Liu H, et al. CircRNA hsa_circRNA_104348 promotes hepatocellular carcinoma progression through modulating miR-187-3p/RTKN2 axis and activating Wnt/β-catenin pathway. Cell Death Dis. 2020;11(12):1065. doi:10.1038/s41419-020-03276-1
   PubMed Web of Science ®Google Scholar
• Liu T, Wang N, Cao J, et al. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas. Oncogene. 2014;33(42):4978–4984. doi:10.1038/onc.2013.446
   PubMed Web of Science ®Google Scholar
• Wang N, Liu T, Sofiadis A, et al. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA. Cancer. 2014;120(19):2965–2979. doi:10.1002/cncr.28800
   PubMed Web of Science ®Google Scholar
• Stoehr R, Taubert H, Zinnall U, et al. Frequency of TERT promoter mutations in prostate cancer. Pathobiology. 2015;82(2):53–57. doi:10.1159/000381903
   PubMed Web of Science ®Google Scholar
• Sabaliauskaite R, Jarmalaite S, Petroska D, et al. Combined analysis of TMPRSS2-ERG and TERT for improved prognosis of biochemical recurrence in prostate cancer. Genes Chromosomes Cancer. 2012;51(8):781–791. doi:10.1002/gcc.21963
   PubMed Web of Science ®Google Scholar
• Tanaka M, Yamashita SI, Yoshinaga Y, et al. Combination of DYRK2 and TERT expression is a powerful predictive marker for early-stage breast cancer recurrence. Anticancer Res. 2022;42(4):2079–2085. doi:10.21873/anticanres.15689
   PubMed Web of Science ®Google Scholar
• Shimoi T, Yoshida M, Kitamura Y, et al. TERT promoter hotspot mutations in breast cancer. Breast Cancer. 2018;25(3):292–296. doi:10.1007/s12282-017-0825-5
   PubMed Web of Science ®Google Scholar
• Zhu J, Zhao Y, Wang S. Chromatin and epigenetic regulation of the telomerase reverse transcriptase gene. Protein Cell. 2010;1(1):22–32. doi:10.1007/s13238-010-0014-1
   PubMed Web of Science ®Google Scholar
• Liu Z, Zhang L, Chen W, et al. miR-195-5p regulates cell proliferation, apoptosis, and invasion of thyroid cancer by targeting telomerase reverse transcriptase. Bioengineered. 2021;12(1):6201–6209. doi:10.1080/21655979.2021.1963908
   PubMed Web of Science ®Google Scholar
• Jang JW, Kim JS, Kim HS, et al. Significance of TERT genetic alterations and telomere length in hepatocellular carcinoma. Cancers. 2021;13:9. doi:10.3390/cancers13092160
   Web of Science ®Google Scholar
• Xiao X, Mo H, Tu K. CTNNB1 mutation suppresses infiltration of immune cells in hepatocellular carcinoma through miRNA-mediated regulation of chemokine expression. Int Immunopharmacol. 2020;89(Pt A):107043. doi:10.1016/j.intimp.2020.107043
   PubMed Web of Science ®Google Scholar
• Paulsson JO, Zedenius J, Juhlin CC. TERT Promoter Mutated Follicular thyroid carcinomas exhibit a distinct microRNA expressional profile with potential implications for tumor progression. Endocr Pathol. 2021;32(4):513–516. doi:10.1007/s12022-021-09695-w
   PubMed Web of Science ®Google Scholar
• Kurihara-Shimomura M, Sasahira T, Shimomura H, Nakashima C, Kirita T. The oncogenic activity of miR-29b-1-5p induces the epithelial-mesenchymal transition in oral squamous cell carcinoma. J Clin Med. 2019;8:2. doi:10.3390/jcm8020273
   Web of Science ®Google Scholar
• Liu P, Xia P, Fu Q, et al. miR-199a-5p inhibits the proliferation of hepatocellular carcinoma cells by regulating CDC25A to induce cell cycle arrest. Biochem Biophys Res Commun. 2021;571:96–103. doi:10.1016/j.bbrc.2021.07.035
   PubMed Web of Science ®Google Scholar
• Cho Y, Park MJ, Kim K, et al. Tumor-stroma crosstalk enhances REG3A expressions that drive the progression of hepatocellular carcinoma. Int J Mol Sci. 2020;21:2. doi:10.3390/ijms21020472
   Web of Science ®Google Scholar
• Sheng W, Zhang ZC, Shi DY, et al. Epigenetic silencing of SFRP5 promotes the metastasis and invasion of chondrosarcoma by expression inhibition and Wnt signaling pathway activation. Chem Biol Interact. 2018;296:1–8. doi:10.1016/j.cbi.2018.08.020
   PubMed Web of Science ®Google Scholar
• Zhou W, Ye C, Li L, et al. Adipocyte-derived SFRP5 inhibits breast cancer cells migration and invasion through Wnt and epithelial-mesenchymal transition signaling pathways. Chin J Cancer Res. 2020;32(3):347–360. doi:10.21147/j.issn.1000-9604.2020.03.06
   PubMed Web of Science ®Google Scholar
• Wang B, Huang G, Wang D, et al. Null genotypes of GSTM1 and GSTT1 contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis. J Hepatol. 2010;53(3):508–518. doi:10.1016/j.jhep.2010.03.026
   PubMed Web of Science ®Google Scholar
• Li X, Song H, Liu Z, Bi Y. miR-1260b promotes cell migration and invasion of hepatocellular carcinoma by targeting the regulator of G-protein signaling 22. Biotechnol Lett. 2018;40(1):57–62. doi:10.1007/s10529-017-2455-6
   PubMed Web of Science ®Google Scholar
• Liu DR, Guan QL, Gao MT, Jiang L, Kang HX. miR-1260b is a potential prognostic biomarker in colorectal cancer. Med Sci Monit. 2016;22:2417–2423. doi:10.12659/MSM.898733
   PubMed Web of Science ®Google Scholar
• Xu L, Xu X, Huang H, et al. MiR-1260b promotes the migration and invasion in non-small cell lung cancer via targeting PTPRK. Pathol Res Pract. 2018;214(5):776–783. doi:10.1016/j.prp.2018.02.002
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Okamoto A, Isonishi S, Ochiai K, Ohtake Y. A novel gene, CRR9, which was up-regulated in CDDP-resistant ovarian tumor cell line, was associated with apoptosis. Biochem Biophys Res Commun. 2001;280(4):1148–1154. doi:10.1006/bbrc.2001.4250
   PubMed Web of Science ®Google Scholar
• Carkic J, Nikolic N, Radojevic-Skodric S, et al. The role of TERT-CLPTM1L SNPs, hTERT expression and telomere length in the pathogenesis of oral squamous cell carcinoma. J Oral Sci. 2016;58(4):449–458. doi:10.2334/josnusd.16-0108
   PubMed Web of Science ®Google Scholar
• Yang YC, Fu WP, Zhang J, Zhong L, Cai SX, Sun C. rs401681 and rs402710 confer lung cancer susceptibility by regulating TERT expression instead of CLPTM1L in East Asian populations. Carcinogenesis. 2018;39(10):1216–1221. doi:10.1093/carcin/bgy084
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang X, Zhang H, et al. Common variations in TERT-CLPTM1L locus are reproducibly associated with the risk of nasopharyngeal carcinoma in Chinese populations. Oncotarget. 2016;7(1):759–770. doi:10.18632/oncotarget.6397
   PubMedGoogle Scholar
• Lee HW, Park WJ, Heo YR, Park TI, Park SY, Lee JH. TERT-CLPTM1 locus polymorphism (rs401681) is associated with the prognosis of hepatocellular carcinoma. Onco Targets Ther. 2017;10:4853–4858. doi:10.2147/OTT.S138956
   PubMed Web of Science ®Google Scholar
• Zhan M, He K, Xiao J, et al. LncRNA HOXA11-AS promotes hepatocellular carcinoma progression by repressing miR-214-3p. J Cell Mol Med. 2018;22(8):3758–3767. doi:10.1111/jcmm.13633
   PubMed Web of Science ®Google Scholar
• Ke AW, Shi GM, Zhou J, et al. Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma. Hepatology. 2009;49(2):491–503. doi:10.1002/hep.22639
   PubMed Web of Science ®Google Scholar